Skip to main content
. 2022 Jul 20;624:122042. doi: 10.1016/j.ijpharm.2022.122042

Table 6.

A list of drug combinations showing synergistic and antagonistic effects against SARS-CoV-2 in cell line studies.

Drug A Drug A mode of action Drug B Drug B mode of action Effect (Drug A + Drug B) References
Remdesivir RdRp inhibitor Ebselen Protease inhibitor Synergistic (Chen et al., 2021)
Remdesivir RdRp inhibitor Disulfiram Protease inhibitor Synergistic (Chen et al., 2021)
Remdesivir RdRp inhibitor Ivermectin Importin α/β1 inhibitor Synergistic (Tan et al., 2021)
Remdesivir RdRp inhibitor Nitazoxanide Entry inhibitor Synergistic (Bobrowski et al., 2021)
Nitazoxanide Entry inhibitor Umifenovir Entry inhibitor Synergistic (Bobrowski et al., 2021)
Nitazoxanide Entry inhibitor Emetine dihydrochloride hydrate Replication inhibitor Synergistic (Bobrowski et al., 2021)
Nitazoxanide Entry inhibitor Amodiaquine Entry inhibitor Synergistic (Bobrowski et al., 2021)
Favipiravir RdRp inhibitor Ivermectin Importin α/β1 inhibitor Synergistic (Jitobaom et al., 2022)
Otamixaban Entry inhibitor Camostat TMPRSS2 inhibitor Synergistic (Hempel et al., 2021)
Otamixaban Entry inhibitor Nafamostat TMPRSS2 inhibitor Synergistic (Hempel et al., 2021)
Remdesivir RdRp inhibitor Brequinar Replication inhibitor Synergistic (Schultz et al., 2022)
Molnupiravir RdRp inhibitor Brequinar Replication inhibitor Synergistic (Schultz et al., 2022)
Cepharanthine Entry inhibitor Nelfinavir Replication inhibitor Synergistic (Ohashi et al., 2021)
Remdesivir RdRp inhibitor Hydroxychloroquine Entry inhibitor Antagonistic (Bobrowski et al., 2021)
Remdesivir RdRp inhibitor Mefloquine Entry inhibitor Antagonistic (Bobrowski et al., 2021)
Remdesivir RdRp inhibitor Amodiaquine Entry inhibitor Antagonistic (Bobrowski et al., 2021)
*RdRp = RNA-dependent RNA polymerase, TMPRSS2 = Transmembrane protease, serine 2